Randomized Study Comparing Two Models of a Travoprost Intraocular Implant to Timolol Maleate Ophthalmic Solution, 0.5%

• Status: Active, not recruiting
• Trial end date: 2024-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase III study to compare the safety and efficacy of intraocular implants containing travoprost at two different elution rates versus Timolol Maleate Ophthalmic Solution, 0.5% (timolol) in reducing elevated intraocular pressure in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Glaukos Corporation
• Treatments: Maleic acid; Ophthalmic Solutions; Timolol; Travoprost

Criteria

Inclusion Criteria:

• Diagnosed with open-angle glaucoma or ocular hypertension.

• C/D ratio ≤ 0.8

• Zero to three preoperative ocular hypotensive medications

Exclusion Criteria:

• Active corneal inflammation or edema.

• Retinal disorders not associated with glaucoma.